<SEC-DOCUMENT>0001157523-17-001796.txt : 20170616
<SEC-HEADER>0001157523-17-001796.hdr.sgml : 20170616
<ACCEPTANCE-DATETIME>20170616082227
ACCESSION NUMBER:		0001157523-17-001796
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170616
FILED AS OF DATE:		20170616
DATE AS OF CHANGE:		20170616

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		17914821

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51575747.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2017 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font><br><br>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 18pt; font-family: Times New Roman"><b>FORM 6-K</b></font><br><br>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-size: 12pt; font-family: Times New Roman">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Dated</b></font><font style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>June
      16, 2017</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Form 20-F &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Yes &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: Times New Roman">
      No &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font>
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt">
      This Form 6-K is hereby filed and incorporated by reference into the
      Registrant&#8217;s Registration Statement on Form F-10 (File No. 333-206994).
    </p>
    <p style="text-indent: 60.0px">

    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated June 6 2017.
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td colspan="3" valign="top" style="text-align: left; padding-left: 0.0px">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td colspan="3" valign="top" style="text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td colspan="3" valign="top" style="text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 3%">
          By:
        </td>
        <td colspan="2" valign="top" style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Celia Economides
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 3%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 5%">
          Name:
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 42%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Celia Economides
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 50%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 5%">
          Title:
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 42%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Vice President, Public Affairs
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center; font-family: Times New Roman; font-size: 10pt">
          2
        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%">
      <tr>
        <td valign="bottom" style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px; width: 7%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 5%">
          &#160;
        </td>
        <td valign="bottom" style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px; width: 88%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 88%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-right: 0.0px; text-align: left; white-space: nowrap; padding-left: 0.0px; width: 7%">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 88%">
          <p style="margin-bottom: 0px; margin-top: 0px">
            News Release &#8211; <b>Voclosporin Remission Data from the Phase
            IIb AURA-LV Study Highlighted at EULAR 2017</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p>
      Exhibit 99.1 included with this report on Form 6-K is hereby
      incorporated by reference as an exhibit to the Registrant&#8217;s Registration
      Statement on Form F-10 (File No. 333-206994), as amended or supplemented.
    </p>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51575747ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2017 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Voclosporin
      Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>-Patients
      on voclosporin achieve remission faster and maintain remission longer
      when compared to control</b></font></i>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>-Data
      presented during late-breaking session</b></font></i>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--June 16, 2017--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (&#8220;Aurinia&#8221; or the
      &#8220;Company&#8221;) a clinical stage biopharmaceutical company focused on the
      global immunology market, presented new duration of remission data from
      its global Phase IIB AURA-LV (AURA) study in lupus nephritis (LN) during
      the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid,
      Spain. The presentation was made during the late-breaking session by
      Prof. Vladimir A. Dobronravov, MD, PhD, DSc, a clinical investigator for
      the study and Vice Director, Research Institute of Nephrology, 1st
      St-Petersburg Pavlov State Medical University.
    </p>
    <p>
      As previously reported, treatment with low dose voclosporin showed
      statistically improved efficacy over the control arm at both 24 and 48
      weeks, with a doubling of remission rates at 48 weeks versus the control
      arm (49% vs 24%). These results were achieved in the presence of low
      doses of corticosteroids and normal, stable renal function. Furthermore,
      of the low-dose voclosporin patients that achieved CR at 24 weeks, 100%
      remained in CR at 48 weeks, establishing durability of clinical
      response. The data presented at EULAR 2017 demonstrated that over the
      course of the 48-week trial, patients on voclosporin stayed in remission
      approximately twice the amount of time as those in the control group.
      These differences were statistically significant versus the control arm.
      Duration of remission as measured by proteinuria is clinically
      meaningful as it may correlate with lower rates of progression to
      Chronic Kidney Disease.<sup>1</sup>
    </p>
    <p>
      The remission results at 48 weeks are summarized below.
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 8pt; width: 100%">
      <tr>
        <td valign="top" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <b>Treatment Group</b>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="top" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <b>Complete Remission</b>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="top" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Duration of Remission through</b><br><b>48 weeks (mean days,
            95%CI)</b><br><b>(measured by UPCR &#8804;.5mg/mg)</b>
          </p>
        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <b>VCS 23.7mg BID</b>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          <b>49%</b>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          <b>123 (96.1,148.4)</b>
        </td>
      </tr>
      <tr>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="middle" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <i><b>p&lt;.001</b></i>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          <i><b>p=.0012</b></i>
        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <b>VCS 39.5mg BID</b>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          40%
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          111 (82.7,129.7)
        </td>
      </tr>
      <tr>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          <i>p=.026</i>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          <i>p=.01</i>
        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <b>Control Group</b>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          24%
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; white-space: nowrap; border-bottom-color: black; padding-left: 0.0px">
          66 (43.0,88.5)
        </td>
      </tr>
      <tr>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="middle" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <i>NA</i>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td valign="middle" style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black; padding-left: 0.0px">
          <i>NA</i>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
      </tr>
    </table>
    </div>
    <p>
      &#8220;Not only have more patients on voclosporin achieved complete remission,
      but they have done so faster. Patients on low-dose voclosporin are also
      maintaining remission for a longer duration&#8212;nearly twice that of the
      control group on average,&#8221; stated Dr. Dobronravov. &#8220;The quicker we can
      bring patients into remission and keep them there, the more likely we
      are to delay or even prevent the deleterious effects of prolonged
      inflammation which can lead to irreversible kidney damage.&#8221;
    </p>
    <p>
      All arms of the study included the current standard of care of
      mycophenolate mofetil (MMF) as background therapy and an aggressive
      steroid taper. Both doses of voclosporin at 48 weeks demonstrated
      continued improvement over the control group across multiple measures.
      The voclosporin treated groups demonstrated statistically significant
      improvement over the control group in speed and rates of complete and
      partial remission (CR and PR, respectively). Proteinuria levels and
      reduction in Systemic Lupus Erythematosus Disease Activity Index
      (SLEDAI) scores, which include non-renal measures of lupus activity,
      also continued to significantly improve over time versus the control
      group. Additional analyses are ongoing and will be presented at future
      medical and scientific meetings.
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      No unexpected safety signals nor adverse events were observed and
      voclosporin was generally well-tolerated, consistent with what is
      expected of patients suffering from active LN while undergoing
      immunomodulation-based therapy. In the voclosporin arms, renal function
      as measured by estimated glomerular filtration rate (eGFR) was stable
      and not significantly different from the control arm following the
      48-week treatment period. There were no electrolyte changes in the
      treatment groups and mean blood pressure was also similar across
      treatment groups through 48 weeks.
    </p>
    <p>
      <i><b>About Voclosporin</b></i>
    </p>
    <p>
      Voclosporin, an investigational drug, is a novel and potentially
      best-in-class calcineurin inhibitor (&#8220;CNI&#8221;) with clinical data in over
      2,200 patients across indications. Voclosporin is an immunosuppressant,
      with a synergistic and dual mechanism of action that has the potential
      to improve near- and long-term outcomes in LN when added to standard of
      care (MMF). By inhibiting calcineurin, voclosporin blocks IL-2
      expression and T-cell mediated immune responses. It has been shown to
      have a more predictable pharmacokinetic and pharmacodynamic
      relationship, an increase in potency, an altered metabolic profile and
      potential for flat dosing compared to legacy CNIs. The Company
      anticipates that upon regulatory approval, patent protection for
      voclosporin will be extended in the United States and certain other
      major markets, including Europe and Japan, until at least October 2027
      under the Hatch-Waxman Act and comparable laws in other countries.
    </p>
    <p>
      <i><b>About Lupus Nephritis (LN)</b></i>
    </p>
    <p>
      LN in an inflammation of the kidney caused by Systemic Lupus
      Erythematosus (&#8220;SLE&#8221;) and represents a serious progression of SLE. SLE
      is a chronic, complex and often disabling disorder and affects more than
      500,000 people in the United States (mostly women). The disease is
      highly heterogeneous, affecting a wide range of organs &amp; tissue systems.
      It is estimated that as many as 60 percent of all SLE patients will
      develop clinical LN requiring treatment. Unlike SLE, LN has
      straightforward disease outcomes (measuring proteinuria) where an early
      response correlates with long-term outcomes. In patients with LN, renal
      damage results in proteinuria and/or hematuria and a decrease in renal
      function as evidenced by reduced estimated glomerular filtration rate
      (eGFR), and increased serum creatinine levels. LN is debilitating and
      costly and if poorly controlled, LN can lead to permanent and
      irreversible tissue damage within the kidney, resulting in end-stage
      renal disease (ESRD), thus making LN a serious and potentially
      life-threatening condition.
    </p>
    <p>
      <i><b>About Aurinia</b></i>
    </p>
    <p>
      Aurinia is a clinical stage biopharmaceutical company focused on
      developing and commercializing therapies to treat targeted patient
      populations that are suffering from serious diseases with a high unmet
      medical need. The company is currently developing voclosporin, an
      investigational drug, for the treatment of LN. The company is
      headquartered in Victoria, BC and focuses its development efforts
      globally. <u>www.auriniapharma.com</u>
    </p>
    <p>
      <i><b>Forward Looking Statements</b></i>
    </p>
    <p>
      This press release contains forward-looking statements, including
      statements related to Aurinia&#8217;s ability to execute a successful Phase
      III program and voclosporin&#8217;s potential differentiation from its
      therapeutic class, Aurinia's analysis, assessment and conclusions of the
      results of the AURA-LV clinical study and timing of voclosporin&#8217;s patent
      protection. It is possible that such results or conclusions may change
      based on further analyses of these data.&#160;Words such as &quot;plans,&quot;
      &quot;intends,&quot; &#8220;may,&#8221; &quot;will,&quot; &quot;believe,&quot; and similar expressions are
      intended to identify forward-looking statements. These forward-looking
      statements are based upon Aurinia&#8217;s current expectations.
      Forward-looking statements involve risks and uncertainties. Aurinia&#8217;s
      actual results and the timing of events could differ materially from
      those anticipated in such forward-looking statements as a result of
      these risks and uncertainties, which include, without limitation, the
      risk that Aurinia&#8217;s analyses, assessment and conclusions of the results
      of the AURA-LV clinical study, the future success of a Phase III study
      and the timing of voclosporin&#8217;s patent protection set forth in this
      release may change based on further analyses of such data, and the risk
      that Aurinia&#8217;s clinical studies for voclosporin may not lead to
      regulatory approval. These and other risk factors are discussed under
      &quot;Risk Factors&quot; and elsewhere in Aurinia&#8217;s Annual Information Form for
      the year ended December 31, 2016 filed with Canadian securities
      authorities and available at <u>www.sedar.com</u> and on Form 40-F with
      the U.S. Securities Exchange Commission and available at <u>www.sec.gov</u>,
      each as updated by subsequent filings, including filings on Form 6-K.
      Aurinia expressly disclaims any obligation or undertaking to release
      publicly any updates or revisions to any forward-looking statements
      contained herein to reflect any change in Aurinia's expectations with
      regard thereto or any change in events, conditions or circumstances on
      which any such statements are based, except as required by law.
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <sup>1</sup>Kidney Int.&#160;2011 Apr;79(8):914-20. doi: 10.1038/ki.2010.525.
      Epub 2011 Jan 19.
    </p>
    <p>
      Persistent proteinuria and dyslipidemia increase the risk of progressive
      chronic&#160;kidney&#160;disease in lupus erythematosus.
    </p>
    <p>
      Reich&#160;HN1,&#160;Gladman DD,&#160;Urowitz MB,&#160;Bargman JM,&#160;Hladunewich MA,&#160;Lou
      W,&#160;Fan SC,&#160;Su J,&#160;Herzenberg AM,&#160;Cattran DC,&#160;Wither
      J,&#160;Landolt-Marticorena C,&#160;Scholey JW,&#160;Fortin PR.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Aurinia Pharmaceuticals Inc.<br><b>Investors:</b><br>Celia
      Economides<br>Vice President, Public Affairs<br><u>ceconomides@auriniapharma.com</u><br>or<br><b>Media:</b><br>Christopher
      Hippolyte, 212-364-0458<br><u>Christopher.hippolyte@inventivhealth.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
